Lymphoproliferative disease in patients with Wiskott-Aldrich syndrome: Analysis of the French Registry of Primary Immunodeficiencies.
暂无分享,去创建一个
A. Fischer | M. Bernard | P. Rohrlich | L. Dupré | N. Mahlaoui | Y. Bertrand | L. Ysebaert | M. Cheminant | B. Neven | D. Moshous | F. Suarez | Z. Vasconcelos | D. Canioni | M. Malphettes | C. Desconclois
[1] A. Fischer,et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. , 2011, Blood.
[2] A. Fischer,et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. , 2010, Blood.
[3] Silvia Giliani,et al. Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. , 2004, Blood.
[4] Kohsuke Imai,et al. Clinical course of patients with WASP gene mutations. , 2004, Blood.
[5] K. Sullivan,et al. A multiinstitutional survey of the Wiskott-Aldrich syndrome. , 1994, The Journal of pediatrics.
[6] F. Candotti. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome , 2017, Journal of Clinical Immunology.
[7] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[8] The French national registry of primary immunodeficiency diseases. , 2010, Clinical immunology.
[9] E. Jaffe,et al. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. , 1985, Cancer investigation.